IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer

Ilan Bruchim*, Rive Sarfstein, Ari Reiss, Eliezer Flescher, Haim Werner

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The present study evaluated the cytotoxic activity of methyl jasmonate (MJ) in endometrial cancer cells and examined the hypothesis that the apoptotic and anti-proliferative actions of MJ in these cell lines can be enhanced by co-targeting the insulin-like growth factor-1 receptor (IGF1R) signaling pathway. MJ had a potent pro-apoptotic effect and exhibited significant toxicity in all cell lines tested. MJ in combination with NVP-AEW541, a selective IGF1R tyrosine kinase inhibitor, had significantly increased cytotoxicity. MJ decreased IGF1R phosphorylation, however, it enhanced AKT phosphorylation and abolished the anti-apoptotic effect of IGF1. These findings suggest that combined IGF1R inhibitor and MJ administration may constitute an attractive modality for treating endometrial cancer.

Original languageEnglish
Pages (from-to)214-219
Number of pages6
JournalCancer Letters
Volume352
Issue number2
DOIs
StatePublished - 1 Oct 2014

Keywords

  • Endometrial carcinoma
  • IGF1 receptor (IGF1R)
  • Insulin-like growth factor-1 (IGF1)
  • Methyl jasmonate
  • NVP-AEW541
  • Uterine serous carcinoma

Fingerprint

Dive into the research topics of 'IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer'. Together they form a unique fingerprint.

Cite this